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are associated with an increased risk of ischemic heart disease. The
concurrence of RLP-C measurement by different separation methods
is not well-described. This analysis assessed RLP-C by 3 commonly
used measurements including immunoseparation (IM [ApoA-I and
ApoB-100 monoclonal antibodies]), vertical auto proﬁle (VAP
[IDLþVLDL3]) and Calculated RLP-C (Total cholesterol minus HDL-C
minus LDL-C) methods using samples from a previously reported
randomized, clinical trial.
METHODS This analysis assessed fasting RLP-C in hyperlipidemic
patients (n¼2,382) treated with ezetimibe/simvastatin (E/S)10/20
mg, E/S þ niacin (N) 2g and N 2g during 24 weeks, and E/S 10/20
mg and E/S þ N 2g during 64 weeks. RLP-C levels, change from
baseline and % change from baseline were evaluated by the IM,
VAP, and Calculated methods. The relationships and agreement
among the 3 methods used in the measurement of these parameters
were assessed by Pearson correlation coefﬁcients and Bland-Altman,
respectively.
RESULTS Cholesterol mass at baseline measured by the VAP and
Calculated methods was w3-4X higher than by IM; all declined with
treatment by 24 weeks with little further reduction at 64 weeks (see
table). RLP-C change and % reduction from baseline were larger when
measured by VAP versus Calculated and IM methods. Although the 3
methods were moderately to strongly correlated (r¼0.37-0.79) for
RLP-C levels and changes, Bland-Altman plots showed little agree-
ment between the methods for RLP-C levels but slightly better
agreement for RLP-C changes (not shown).
CONCLUSIONS RLP-C deﬁned by IM, VAP and Calculated methods
differs in mass and response to pharmacologic intervention. Given the
relationship between RLP-C and IHD risk, standardization of methods
is needed for RLP-C use in risk assessment.GW26-e2366
Changes in Carotid Plaque Lipid Content in Subjects Who Continued and
Discontinued Statin Therapy
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The Department of Geriatric Cardiology & Department of Radiology,
Chinese PLA General Hospital, Beijing, China
OBJECTIVES Changes in carotid plaque lipid-rich necrotic core
(LRNC) as assessed by magnetic resonance imaging (MRI) were
investigated in subjects who continued and discontinued statin
therapy for 2 years after a prospective study.
METHODS The Rosuvastatin Evaluation of Atherosclerotic Chinese
Patients (REACH) study in 32 lipid treatment naïve subjects with
LRNC showed a signiﬁcant reduction in LRNC during 24 months (M) of
rosuvastatin therapy. All subjects received a clinical follow-up (F/U)
visit and a repeat carotid MRI scan at 48 M as planned REACH-F/U.
Despite receiving a strong recommendation to continue the statin
therapy at 24 M when REACH was completed, only 15 subjects
continued taking statins (rosuva.¼9, simva.¼4 and atorva.¼2) in
REACH-F/U and 17 discontinued. Lipids and LRNC, both in volume (V)
and % (LRNC-V/Wall V100%), were compared between the statin-
continued and -discontinued groups at 48 M.
RESULTS There were no signiﬁcant differences in demographic,
clinical characteristics, lipids and plaque changes during 24 M in
REACH between the statin-continued and -discontinued groups in
REACH-F/U. Not surprisingly, at 48 M, Total-Cholesterol (C), LDL-C
and triglycerides were signiﬁcantly lower in subjects who continued
statin than those discontinued (16343 vs. 20730 mg/dl, p¼0.002),
(9336 vs. 13122 mg/dl, p¼0.001) and (8527 vs. 14365 mg/dl,
p¼0.003), while HDL-C levels were similar. LRNC-V and %LRNC
decreased signiﬁcantly from 24 M in the statin-continued group
(10176 mm3 at 24 M vs. 7665 mm3 at 48 M, p¼0.001) and
(17.311.9% at 24 M vs. 12.67.6% at 48 M, p¼0.04). By contrast,
subjects who discontinued statin showed non-statistically signiﬁ-
cant increase in LRNC-V and %LRNC (10393 mm3 at 24 M vs.
112106 mm3 at 48 M, p¼0.4) and (15.411.3% at 24 Mvs.
16.711.4% at 48 M, p¼0.07). Furthermore, the changes in LRNC-V
and %LRNC from 24 to 48 M were signiﬁcantly different between
the statin-continued and -discontinued groups in REACH-F/U
(-2518 vs. 914 mm3, p<0.001) and (-4.6 8.2% vs. 1.32.8%,
p¼0.009).
CONCLUSIONS Continued statin therapy leads to continued decrease
in LRNC, which indicates improved plaque stability. The REACH-F/U
results provided vascular biological evidence to strongly support long-
term statin therapy.GW26-e3950
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OBJECTIVES The oral direct thrombin inhibitor dabigatran has a pre-
dictable anticoagulant effect and may be an alternative medication to
warfarin for non-valvular atrial ﬁbrillation (AF) patients with intracardiac
thrombus. The objective is to compare the dabigatran, administered at a
ﬁxed dose of 150 mg twice daily (bid) with dose-adjusted warfarin (with a
target international normalized ratio INR level of 2.0 to 3.0).
METHODS In the trial, 41 patients who had intracardiac thrombus
detected by transesophageal echocardiography (TEE) were enrolled.
Among them, 19 patients received dabigatran 150 mg bid and the
remaining 22 patients received warfarin based on the patients’ indi-
vidual choice. Repeated TEE was performed at 3 months. The patients
was assessed after 1 month and then 3 months in the clinic; meanwhile
they were requested to contact the investigator immediately if symp-
toms developed that were suggestive of stroke, thromboembolism or
major bleeding. All statistical analyses were conducted with SPSS Sta-
tistics version 17.0 software. The thrombus dissolution ability, repre-
sented by the ratio of decreased thrombus area to original area, was
compared by Wilcoxon W test between the 2 groups. Difference with p
value < 0.05 (2-sided) was considered statistically signiﬁcant.
RESULTS Mean age of the study population was 57.77.4 years, with
36 (87.8%) male and 17 (41.5%) patients who had persistent AF, with
no differences between the 2 groups. Thrombus area ranges from 0.1
to 4.48 cm2 and the locations of thrombi were mainly in left atrial
appendage (LAA). The thrombus area in warfarin group were larger
than in dabigatran group (1.451.04 vs. 0.640.54, p < 0.05). Mean
number of INR examination values obtained in the warfarin group was
10 during the therapy course. Time in therapeutic range of INR (TTR)
was above 60%. Complete thrombus resolution was documented by
repeated TEE in 17 patients in dabigatran group (17 of 19) and 17 pa-
tients in warfarin group (17 of 22). The ability of thrombus dissolution,
represented by the ratio of decreased thrombus area to original area,
was similar between the 2 groups (p > 0.05). Any bleeding, occurred in
7 patients receiving dabigatran and in 8 patients receiving warfarin.
No major or fatal bleeding occurred in both two groups. One patient in
the warfarin group experienced ischemic stroke. Four patients in the
dabigatran group had gastrointestinal discomfort. Only one patient
discontinued dabigatran for about two weeks and needed drug
intervention, and after 3-month anticoagulation, a secondary TEE
detected an increased thrombus.
CONCLUSIONS Dabigatran has similar effect compared with warfarin
for the treatment of intracardiac thrombus in patients with non-
valvular AF. Uninterrupted dabigatran is particularly essential and
crucial for ﬁbrinolysis and drug discontinuance would affect
thrombus dissolution effect. It should be noticed that dabigatran lead
to gastrointestinal discomfort event.
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Comparison of Ticagrelor with Clopidogrel in the Treatment of Patients
with Acute Coronary Syndrome in Platelet Reactivity
Jingjing Li, Xiaowen Geng, Jie Gao, Yilun Chen, Yihong Ren
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OBJECTIVES To compare the inhibitory effect of ticagrelor and clo-
pidogrel on the platelet of patients with acute coronary syndro-
me(ACS) after percutaneous coronary artery intervention(PCI).
METHODS 255 cases of patients with ACS admitted in our hospital
from March 2014 to August 2014 were selected for this study, in which
85 cases were treated by ticagrelor and aspirin and the other 170 cases
were treated by clopidogrel and aspirin respectively. All the patients
were given PCI treatment, and the thrombelastography(TEG) were
detected 2 days after PCI and oral administration of load dosage of
antiplatelet drugs, the platelet inhibition ratio through ADP and AA
pathway were observed and compared between two groups.
RESULTS Adenosine diphosphate(ADP)-induced platelet inhibition
ratio in clopidogrel group was signiﬁcantly lower than that of in
ticagrelor group (66.6025.57% vs 82.1018.87%, P<0.05). Arach-
idonic acid(AA)-induced platelet inhibition ratio in clopidgrel was
similar to that of in ticagrelor group (88.7023.89% vs 90.3218.09%,
P>0.05). There were signiﬁcant differences between clopidogrel
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induced platelet inhibition ratio<30% (1.2% vs 8.2%, P<0.05). There
were signiﬁcant differences between clopidogrel group and ticagrelor
group in the percentages of patients with ADP-induced platelet inhi-
bition ratio <50% (29.4% vs 10.6%, P<0.05). There were also signiﬁ-
cant differences between clopidogrel group and ticagrelor group in
the percentages of patients with ADP-induced platelet inhibition
ratio>75% (41.8% vs 69.4%, P<0.05).
CONCLUSIONS ① Ticagrelor had greater inhibitory effect on the pa-
tients with ACS after PCI than Clopidogrel. ② Higher residual platelet
activity (HRPA) phenomenon also can be seen in the ticagrelor treatment
patients, although that is evenmore in clopidogrel treatment patients.
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A Meta-analysis of Randomized Clinical Trials of Dual Antiplatelet Therapy
in Patients with Drug-Eluting Stent Implantation
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OBJECTIVES The purpose of this study was to perform a meta-anal-
ysis comparing short-term versus long-term dual antiplatelet therapy
(DAPT) to identify the optimal duration of DAPT in patients with Drug-
Eluting Stent (DES) implantation.
METHODS This study included 15,870 patients from 7 randomized
clinical trials (RCT) comparing short-term DATP (S-DAPT) versus long-
term DATP (L-DAPT) following drug-eluting stents. We examined the
odds ratio (OR) and 95% conﬁdence intervals (Cls) of clinically sig-
niﬁcant bleeding (CSB) and stent thrombosis as primary endpoints.
Myocardial infarction, stroke, cardiovascular mortality and all-cause
mortality were evaluated as secondary endpoints.
RESULTS Compared with L-DAPT, S-DAPT had a decreased risk of CSB
(OR: 0.57 [95% CI: 0.40 to 0.81]; p < 0.01). The rates of stent throm-
bosis (OR: 1.20 [95% CI: 0.77 to 1.88]; p > 0.05), myocardial infarction
(OR: 1.13 [95% CI: 0.88 to 1.44]; p > 0.05), stroke (OR: 0.88 [95% CI:
0.57 to 1.36]; p > 0.05), cardiovascular mortality (OR: 0.99 [95% CI:
0.72 to 1.36]; p > 0.05) and all-cause mortality (OR: 0.93 [95% CI: 0.74
to 1.18]; p > 0.05) were similar.
CONCLUSIONS S-DAPT for treatment in patients with DES implanta-
tion is associated with a signiﬁcant reduction of CSB compared with
L-DAPT.
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The lowering lipid efﬁcacy of low-dose simvastatin and ezetimibe
compared to high-dose simvastatin alone: A meta-analysis
Ning Zhang, Qizhu Tang
Renmin Hospital of Wuhan University, Wuhan 430060, China
OBJECTIVES The ezetimibe/simvastatin combination tablet and high-
dose simvastatin monotherapy represent two major options for treat-
ment of patients with hyercholesterolemia. The lowering lipid effect of
direct comparative studies between ezetimibe/simvastatin (10/10mg)
and high-dose simvastatin(40mg or 80mg) therapies have not been
reported. To evaluate whether low-dose simvastatin/ezetimibe 10/
10mg would achieve the same lowering lipid efﬁcacy compared to
simvastatin 40mg or 80mg in treatment of patients with dyslipidemia.
METHODS Randomized controlled trials (RCTs) regarding to the pa-
tients with dyslipidemia in treatment of ezetimibe and simvastatin
were retrieved in PubMed, EMBASE and Cochrane Central Register of
Controlled Trials (CENTRAL). We also searched the reference lists of
relevant papers. Data was extracted by two reviewers independently.
Statistical analysis was performed using RevMan 5.2.
RESULTS 8 RCTs including 202 high-dose simvastatin controls and
200 low-dose simvastatin / ezetimibe patients were enrolled in our
meta-analysis. Low density lipoprotein - cholesterol (MD, -0.27; 95%
CI, -3.82 to 3.28; P ¼0.88), high density lipoprotein-cholesterol
(MD, 0.32; 95%CI, -1.32 to 1.95; P ¼0.88), the total cholesterol
level (MD, 0.76; 95%CI, -4.14 to 5.65; P ¼0.76), Apolipoprotein B (MD,
-1.70; 95 %CI, -7.10 to 3.71; P ¼0.54) and apolipoprotein A-I level (MD,
-2.75; 95%CI, -9.72 to 4.23; P ¼0.44) were at the same level after the
low-dose ezetimibe / simvastatin 10/10mg and simvastatin 40mg or 80
mg treatment respectively. However, the maximal dose of simvastatin
can reduce the teriglyrides effectively compared to low-dose simva-
statin/ezetimibe (MD, 14.35; 95%CI, 9.51 to 19.20; P <0.00001).
CONCLUSIONS Our study demonstrate ezetimibe/simvastatin
10/10mg can reach the same lowering lipid parameters such as LDL-C,total cholesterol, Apoliprotein B compared to the maximal-dose sim-
vastin 40mg or 80 mg. These results suggest that ezetimibe/simva-
statin 10/10mg is comparable to the high-dose simvastatin 40mg or
80mg, however, the maximal dose of simvastatin can reduce the tri-
glycerides effectively compared to low-dose simvastatin/ezetimibe.
Two agents can reduce ApoB level and increase the anti-atheroscle-
rosis lipidprotein ApoA-I, and two treatment strategies have same
favorable effect on lipoprotein proﬁles.
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Effectiveness and safety of tolvaptan in chinese heart failure patients with
reduced left ventricular systolic function
Lijin Zeng, Zhibin Chen, Jingguo Wu, Wen Yang, Zhenyu Li
First Afﬁliated Hospital of Sun Yet-sen University
OBJECTIVES To examine the efﬁcacy and safety of tolvaptan in acute
decompensated heart failure patients with reduced left ventricular
systolic function.
METHODS A total of 145 hospitalized acute decompensated heart
failure patients were randomly assigned to either a tolvaptan(n¼79) or
a control group(n¼66) which used conventional treatment only.
Baseline clinical characteristics were not different between the two
groups. We divided these patients based on the left ventricular ejec-
tion fraction (EF) by echocardiography.
RESULTS There was no signiﬁcant difference of daily urine volume
between the tolvaptan and control groups in patients with preserved
EF ( 50%).The urine volume was signiﬁcantly higher in the tolvaptan
group than in the control group in those with reduced EF (< 50%)(P <
0.05 ).In the safety proﬁle, the incidence rate of thirst was higher in
the tolvaptan group than that in control group (21.5% versus 7.6%,
P<0.05). The incidence of hypernatremia( 150 mEq/L) in tolvaptan
group was no signiﬁcant difference than that in control group (6.3%
versus 3.0%, P>0.05).
CONCLUSIONS This study reveals that tolvaptan is more effec-
tive than conventional treatment in acute decompensated heart failure
patients with reduced left ventricular systolic function and it is safety.
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Effects of Shensongyangxin capsule on heart rates variability and insomnia
in maintenance hemodialysis patients
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OBJECTIVES To investigate the efﬁcacy and safety of Shenson-
gyangxin capsule (SSYX) on heart rate variability (HRV) and insomnia
in maintenance hemodialysis patients.
METHODS sixty-three maintenance hemodialysis patients in the third
afﬁliated hospital of Sun Yat-Sen University from 2013 June to
December were divided into two groups, SSYX treatment group(n¼33)
and control group(n¼30). SSYX treatment group were received SSYX 4
capsules four times a day for eight weeks, all patients received 24-h-
holter test and Pittsburgh sleep quality index were measured at both
baseline and eight weeks in these sixty-three patients.
RESULTS SSYX can improve heart rate variability [SDNN (93.21.4)
vs.(82.413.1) ms, SDNNi (41.212.8) vs. (28.412.2)ms, SDANNi
(81.321.1) vs. (73.220.7)ms, RMSSD (28.313.2)vs.(21.811.9)ms,
PNN50 (9.67.1) vs.(7.15.8)%, P<0.05], SSYX can decrease the inci-
dence of arrhythmia [premature atrial contraction(60.6% vs.24.2%),
atrial tachycardia (45.5% vs.12.1%), premature ventricular contrac-
tion(9.1% vs.3%), ventricular tachycardia(21.2% vs.9.1%), atrial-ven-
tricular blocker (60.6% vs.24.2%), P<0.05], SSYX also improved sleep
quality signiﬁcantly[PSQI (6.282.12) vs.( 14.392.84), P<0.05]. There
was no severe adverse events registered during the study.
CONCLUSIONS Clinical use of SSYX was safe and effective for treating
hemodialysis patients with decrease HRV and insomnia.
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Effects of dabigatran on coagulation assays in aged patients with atrial
ﬁbrillation : Two cases report
Xiaoping Hou, Xuan Wei, Yanyan Li
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OBJECTIVES To report the effects of dabigatran etexilate on routine
coagulation assays in two aged patients with atrial ﬁbrillation.
METHODS The data of routine coagulation assays from two aged cases
treated with dabigatran etexilate were retrospectively reviewed,
